A carregar...
Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
BACKGROUND: BAY 81–8973 (Kovaltry) is an unmodified full-length recombinant factor VIII (rFVIII) for treatment of hemophilia A. The BAY 81–8973 manufacturing process results in a product of enhanced purity with a consistently high degree of branching and sialylation of N-linked glycans. This study e...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435118/ https://ncbi.nlm.nih.gov/pubmed/30962676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S188171 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|